source
- Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger🤝 OmniAb’s Lilly pact: The California drug discovery shop has an ion channel collaboration and licensing agreement in place with the GLP-1 giant. Eli Lilly will pay up to $370 million ...Endpoints · 30m ago↗ source
- Celcuity awaits FDA review for second factory to launch cancer drugCelcuity has provided further details on why the commercial rollout of its recently approved cancer drug is slower than investors initially anticipated. The drugmaker said it is waiting for the FDA…Endpoints · 1h ago↗ source
- Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsSlate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…